Beat The Denominator

In the telehealth sector, Hims & Hers (HIMS) is presented as the superior investment right now due to its more stable cash-pay business model. This model avoids the significant risk of insurance claim denials that is currently hurting competitor LifeMD (LFMD) in the popular GLP-1 weight-loss drug market. LFMD recently experienced a sharp stock drop after cutting its revenue guidance, highlighting the challenges in its business. With a stronger guided revenue growth of 45%, HIMS offers a more predictable and robust outlook. A key potential catalyst for LFMD to watch for is the sale of its slow-growing legacy business, WorkSimply.

Consider buying shares of Oddity (ODD), as its recent -22% price drop appears disconnected from its strong financial performance and raised future guidance. The company's AI-powered, direct-to-consumer business model drives superior profit margins and customer loyalty, making it a more compelling investment than competitor ELF. ODD is growing revenue over 20% and is set to launch a new dermatology brand in the second half of the year, providing a potential future catalyst. Management also has a $103 million share buyback program in place, which could support the stock price at these lower levels. Adding a high-growth name like ODD can provide valuable diversification for portfolios concentrated in other sectors.

Hims & Hers Health (HIMS) is a long-term investment focused on becoming a leader in preventative and personalized healthcare. The stock appears significantly undervalued based on its 2030 financial targets, making the recent price drop a potential entry point for investors. Key growth drivers to watch are the expansion of personalized GLP-1 weight loss treatments, the launch of a new lab testing business, and the introduction of menopause therapies. A major future catalyst is the planned launch of generic semaglutide in Canada in early 2026. One analyst noted they would consider buying more shares of HIMS under $50.

The recent stock price drop in Hims & Hers Health (HIMS) presents a potential long-term buying opportunity for investors. Despite short-term market concerns, the company's fundamental growth in revenue and subscribers remains strong. Future growth is expected from the launch of a new longevity product line and expansion into Hormone Replacement Therapy (HRT). The company is also beginning its international expansion into Canada, starting with its weight loss offerings. These catalysts support a bullish long-term outlook, suggesting the core investment thesis is as strong as ever.

For long-term growth, consider holding MSTR common stock as a leveraged play on Bitcoin, using the "Buy-Borrow-Die" strategy to generate tax-free income by borrowing against your shares. This high-conviction strategy is dependent on Bitcoin's appreciation, with speculation that a $200,000 BTC price could double MSTR's value. For stable, tax-efficient retirement income, MSTR's preferred stocks can provide qualified dividends that are potentially tax-free for retirees. The preferred stock STRF is highlighted for its high, stable yield, while Strike is noted as a good value for those wanting some Bitcoin upside. A powerful approach is to combine both, using preferred stock dividends for living expenses and borrowing against the common stock for larger purchases.

For investors seeking diversification, consider uncorrelated opportunities in consumer goods, energy, and specialized tech. SharkNinja (SN) is a fast-growing consumer brand with strong margins, offering a stable holding that is still considered undervalued. For a value play in the energy sector, Tidewater (TDW) has pulled back recently, presenting an attractive entry point to capitalize on the supply shortage of offshore service vessels. For those with a higher risk tolerance, the Kazakhstani super-app Kaspi (KSPI) is a contrarian opportunity, as the stock is down due to expansion uncertainty despite its massive profitability. Finally, Gambling.com (GAMB) offers a cheap, high-margin "picks and shovels" way to invest in the growing online betting trend without direct operator risk.

The recent market-driven drop in MicroStrategy (MSTR) presents a potential buying opportunity for long-term investors. A key bullish catalyst is the company's decision to halt new share offerings until the stock price surpasses $600, protecting current shareholders from dilution. Significant insider buying from board members signals strong conviction that the stock is currently undervalued. As a leveraged play on Bitcoin (BTC), the company's success is tied to the asset, which has a conservative price target of $150,000 by the end of 2025. Based on the company's own valuation models, MSTR stock could have a potential 6x return from its current levels.

MicroStrategy (MSTR) presents a compelling investment opportunity following significant positive updates to its corporate strategy. The company has effectively paused its share issuance program, which could allow the stock to rise 30-40% before selling pressure from new shares resumes. Furthermore, MSTR raised its full-year 2025 Bitcoin (BTC) yield target to an impressive 30%, aiming to significantly grow its crypto holdings. This high yield offers a way to outperform holding Bitcoin directly, helping to justify the stock's premium valuation. For investors seeking enhanced Bitcoin exposure, MSTR provides a clear strategy for appreciation and yield generation.

Consider buying Bitcoin (BTC) or MicroStrategy (MSTR) near the end of the U.S. trading day to potentially capitalize on a recurring daily price dip. For investors interested in the telehealth sector, LifeMD (LFMD) is presented as a more attractive and cheaper alternative to Hims & Hers Health (HIMS) at current valuations. Investors are advised to be cautious about adding to HIMS near its all-time high, as it may be due for a pullback. Similarly, the investment opportunity in Figma was at its IPO price, and it is no longer considered an attractive buy at its current elevated price. This leaves LFMD as the primary "buy" recommendation from these insights.

Consider an investment in Marathon Digital (MARA), as it trades at a valuation nearly equal to the Bitcoin it holds, essentially offering its large-scale mining operation for free. This is a higher-risk, higher-reward play due to the company's strategy of lending out its Bitcoin and issuing new shares to fund operations. The success of this investment is fundamentally tied to a rising price for Bitcoin (BTC), which is the primary catalyst. For investors seeking a lower-risk alternative, MicroStrategy (MSTR) is positioned as a "blue chip" that simply holds Bitcoin without the added operational risks.

The recent pullback in MicroStrategy (MSTR) presents a significant buying opportunity, as the company continues its aggressive strategy of accumulating Bitcoin. A recent purchase of 21,021 Bitcoin at an average price of ~$117k demonstrates strong institutional conviction at these levels. Investors could consider taking profits on more speculative, "higher octane" Bitcoin-related stocks that may be overvalued. It is recommended to reinvest those gains into MSTR, which is viewed as the "blue chip" leader in the Bitcoin treasury sector. The long-term bull case is tied to Bitcoin's potential to reach $1 million, which would position MSTR as a potential trillion-dollar company.

For Bitcoin exposure, Marathon Digital (MARA) is a compelling value play, trading near its net asset value. This is a clear, actionable idea for investors bullish on crypto. Finally, SoFi (SOFI) is a long-term growth story with clear catalysts. I'm crafting a concise,

The core investment thesis is a major Bitcoin supply shock, making any short-term price weakness a strategic buying opportunity before large-scale institutional buying begins. A significant catalyst to watch is a potential $2.5 billion Bitcoin purchase associated with a new entity, STRC, which could occur as early as this Tuesday. It was also claimed that Trump Media & Technology Group (DJT) has already purchased $2 billion worth of Bitcoin for its treasury. For stock market exposure, consider "virtuous miners" like Riot Platforms (RIOT) and Marathon Digital (MARA), which accumulate Bitcoin on their balance sheets. Additionally, MicroStrategy (MSTR) remains a primary vehicle for gaining leveraged exposure to Bitcoin through the equity market.

A key catalyst for MicroStrategy (MSTR) is its earnings report this Thursday, where new accounting rules could show a massive paper profit instead of an expected loss. This event is coupled with an imminent, very large Bitcoin purchase by the company, which could provide a significant boost to BTC's price. For income-focused investors, consider MicroStrategy's new preferred stock (STRC), which is designed to be a stable instrument trading near its $100 par value. STRC offers a high initial yield of 9% as a tax-advantaged qualified dividend, positioning it as a strong alternative for stable income.

Consider MicroStrategy (MSTR) ahead of its July 31st earnings, as a new accounting rule could create a surprise multi-billion dollar gain that may drive the stock higher. Marathon Digital (MARA) offers a compelling investment, as its stock trades close to the value of its Bitcoin holdings, providing a potential margin of safety. The company's recent 0% interest convertible bond was a savvy move to acquire more Bitcoin, making any recent weakness a potential buying opportunity. For TransMedics (TMDX), its strong long-term guidance for 3x growth by 2028 and potential as an acquisition target are key bullish factors. Investors may find an attractive entry point in TMDX or SoFi (SOFI) if their stocks pull back following their late-July earnings reports.

Recent price drops in Hims & Hers (HIMS) may present a buying opportunity for long-term investors. The market appears overly focused on its GLP-1 business, ignoring significant growth potential in other areas like hormone therapy and urgent care. Consider an investment in Viatris (VTRS), which recently won a major patent battle against Novo Nordisk for its blockbuster drug semaglutide. This victory is a significant catalyst for a generic version of Wegovy in the U.S. that is not yet fully priced into the stock. The weakening patent monopoly for major GLP-1 drugs is creating key opportunities for these more diversified telehealth and generic providers.

MicroStrategy's new preferred stock, STRC, offers a potential short-term gain, as it is priced at $90 in its offering but is designed to trade near $100. A significant catalyst for Bitcoin is expected in early August, when MicroStrategy plans to use the offering's proceeds for a large BTC purchase. For long-term investors, MSTR common stock represents a leveraged investment in Bitcoin due to the company's core mission of asset accumulation. This strategy continuously funnels capital from traditional finance (TradFi) into Bitcoin, providing consistent buying pressure. The overwhelming demand for the STRC offering signals strong institutional validation for this aggressive Bitcoin acquisition model.

For investors interested in companies holding cryptocurrency, Riot Platforms (RIOT) is presented as a favorite Bitcoin miner well-positioned to grow its holdings. As a more established play, MicroStrategy (MSTR) is trading at a historically low valuation premium, suggesting a potential entry point for a bounce. KULR Technology Group (KULR) offers a unique recovery opportunity, with its recent stock decline seen as a technical overreaction and a full recovery anticipated above $8 per share. For aggressive investors bullish on Ethereum, GameSquare Holdings (GAME) has the highest growth potential but also carries significant small-cap risk. Lastly, those who believe the Solana ecosystem will outperform should consider DeFi Development Corp (DFDV) as the primary way to gain exposure to that theme.

The recent 14% drop in Marathon Digital (MARA) is considered a significant buying opportunity, as the company plans to acquire more Bitcoin with newly raised capital. For long-term investors, Hims & Hers Health (HIMS) is a high-conviction but volatile investment aimed at disrupting the traditional healthcare industry. Conversely, it is recommended to avoid Enphase Energy (ENPH) in the short term due to significant headwinds from tariffs and competition from Tesla. The stock is currently in a "valley of despair," and it may be too early to invest until it potentially bottoms out in the low $30s. A potential long-term strategy for ENPH involves watching for a future entry point, possibly through long-dated call options for late 2027 or 2028.

The upcoming Figma IPO presents a compelling investment as it is rapidly winning the design software market from its rival, Adobe. Consider buying into the IPO, which is expected to price between $25 and $28 per share, backed by 46% year-over-year revenue growth and a strong 132% net dollar retention rate. The company's "sticky" platform and elite customer base suggest a durable competitive advantage over the much slower-growing Adobe (ADBE). Given its strong fundamentals, Figma appears attractively valued compared to peers in the software sector. There is also potential for the stock to be initially mispriced by the market, creating an opportunity for significant upside similar to the recent Circle IPO.